2011 年多囊肾病：将点连接起来以实现多囊肾病治疗。
Polycystic kidney disease in 2011: Connecting the dots toward a polycystic kidney disease therapy.
机构信息
Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
出版信息
Nat Rev Nephrol. 2011 Dec 13;8(2):66-8. doi: 10.1038/nrneph.2011.196.
Abstract
Understanding the complex interactions between the various pathways disrupted in polycystic kidney and liver disease is essential to identify and optimize therapies for these disorders. Studies published in the past year have demonstrated a functional interaction between the main proteins implicated in these diseases and identified novel therapeutic approaches.
摘要
了解多囊肾病和肝病中各种途径紊乱的复杂相互作用对于确定和优化这些疾病的治疗方法至关重要。过去一年发表的研究表明，这些疾病中主要涉及的蛋白质之间存在功能相互作用，并确定了新的治疗方法。
相似文献
1
Polycystic kidney disease in 2011: Connecting the dots toward a polycystic kidney disease therapy.2011 年多囊肾病：将点连接起来以实现多囊肾病治疗。
Nat Rev Nephrol. 2011 Dec 13;8(2):66-8. doi: 10.1038/nrneph.2011.196.
2
Understanding pathogenic mechanisms in polycystic kidney disease provides clues for therapy.了解多囊肾病的致病机制为治疗提供了线索。
Curr Opin Nephrol Hypertens. 2006 Jul;15(4):456-63. doi: 10.1097/01.mnh.0000232888.65895.e7.
3
Molecular mechanisms of polycystic kidney disease.多囊肾病的分子机制
Biochim Biophys Acta. 2011 Oct;1812(10):1201. doi: 10.1016/j.bbadis.2011.08.004.
4
Manipulation of renal gene expression using oligonucleotides.使用寡核苷酸对肾脏基因表达进行调控。
Methods Cell Biol. 2019;154:109-120. doi: 10.1016/bs.mcb.2019.05.006. Epub 2019 Jun 17.
5
Polycystic kidney disease: new knowledge and future promises.多囊肾病：新知识与未来的承诺。
Curr Opin Genet Dev. 2019 Jun;56:69-75. doi: 10.1016/j.gde.2019.06.007. Epub 2019 Aug 30.
6
[Recent advances in molecular pathogenesis and treatment of polycystic kidney disease].[多囊肾病分子发病机制与治疗的最新进展]
Rev Med Chir Soc Med Nat Iasi. 2008 Jan-Mar;112(1):11-20.
7
[Clinical guidelines for the management of polycystic kidney disease].[多囊肾病管理临床指南]
Nihon Jinzo Gakkai Shi. 2011;53(4):556-78.
8
Polycystic Kidney Disease: Lessons Learned from Caenorhabditis elegans Mating Behavior.多囊肾病：从秀丽隐杆线虫交配行为中学到的经验教训。
Curr Biol. 2015 Dec 21;25(24):R1168-70. doi: 10.1016/j.cub.2015.09.061.
9
Polycystic kidney diseases: from molecular discoveries to targeted therapeutic strategies.多囊肾病：从分子发现到靶向治疗策略
Cell Mol Life Sci. 2008 Feb;65(4):605-19. doi: 10.1007/s00018-007-7362-x.
10
Dyspnea in a 43-year-old woman with polycystic kidney disease.一名患有多囊肾病的43岁女性的呼吸困难。
Chest. 2009 Jan;135(1):238-243. doi: 10.1378/chest.08-1223.
引用本文的文献
1
DNA methyltransferase 1 (DNMT1) promotes cyst growth and epigenetic age acceleration in autosomal dominant polycystic kidney disease.DNA 甲基转移酶 1（DNMT1）促进常染色体显性多囊肾病中囊肿的生长和表观遗传年龄加速。
Kidney Int. 2024 Aug;106(2):258-272. doi: 10.1016/j.kint.2024.04.017. Epub 2024 May 21.
2
Natural Peptide Toxins as an Option for Renewed Treatment of Type 2 Vasopressin Receptor-Related Diseases.天然肽毒素作为重新治疗2型血管加压素受体相关疾病的一种选择。
Biology (Basel). 2023 Apr 3;12(4):544. doi: 10.3390/biology12040544.
3
Transcription factor FoxM1 promotes cyst growth in PKD1 mutant ADPKD.转录因子 FoxM1 促进 PKD1 突变型 ADPKD 的囊肿生长。
Hum Mol Genet. 2023 Mar 20;32(7):1114-1126. doi: 10.1093/hmg/ddac273.
4
A snake toxin as a theranostic agent for the type 2 vasopressin receptor.一种蛇毒素作为 2 型血管加压素受体的治疗诊断试剂。
Theranostics. 2020 Sep 18;10(25):11580-11594. doi: 10.7150/thno.47485. eCollection 2020.
5
Deficient transient receptor potential vanilloid type 4 function contributes to compromised [Ca] homeostasis in human autosomal-dominant polycystic kidney disease cells.瞬时受体电位香草酸亚型 4 功能缺陷导致常染色体显性遗传多囊肾病细胞内钙稳态失衡。
FASEB J. 2018 Aug;32(8):4612-4623. doi: 10.1096/fj.201701535RR. Epub 2018 Mar 19.
6
Identification of targets of IL-13 and STAT6 signaling in polycystic kidney disease.鉴定白细胞介素 13 和 STAT6 信号通路在多囊肾病中的作用靶点。
Am J Physiol Renal Physiol. 2018 Jul 1;315(1):F86-F96. doi: 10.1152/ajprenal.00346.2017. Epub 2018 Mar 7.
7
Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.赖氨酸甲基转移酶SMYD2促进常染色体显性多囊肾病中的囊肿生长。
J Clin Invest. 2017 Jun 30;127(7):2751-2764. doi: 10.1172/JCI90921. Epub 2017 Jun 12.
8
The importance of total kidney volume in evaluating progression of polycystic kidney disease.总肾体积在评估多囊肾病进展中的重要性。
Nat Rev Nephrol. 2016 Nov;12(11):667-677. doi: 10.1038/nrneph.2016.135. Epub 2016 Oct 3.
9
Functional and therapeutic importance of purinergic signaling in polycystic kidney disease.嘌呤能信号在多囊肾病中的功能及治疗意义
Am J Physiol Renal Physiol. 2016 Dec 1;311(6):F1135-F1139. doi: 10.1152/ajprenal.00406.2016. Epub 2016 Sep 21.
10
The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction.近端小管是肾脏疾病损伤和进展的主要靶点：肾小球肾小管连接的作用。
Am J Physiol Renal Physiol. 2016 Jul 1;311(1):F145-61. doi: 10.1152/ajprenal.00164.2016. Epub 2016 May 18.
本文引用的文献
1
Macrophages promote cyst growth in polycystic kidney disease.巨噬细胞促进多囊肾病囊肿生长。
J Am Soc Nephrol. 2011 Oct;22(10):1809-14. doi: 10.1681/ASN.2011010084. Epub 2011 Sep 15.
2
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.托伐普坦治疗常染色体显性遗传多囊肾病：三年经验。
Clin J Am Soc Nephrol. 2011 Oct;6(10):2499-507. doi: 10.2215/CJN.03530411. Epub 2011 Sep 8.
3
Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways.嘧啶并抑制成年多囊肾病通过调节 STAT 信号通路。
Hum Mol Genet. 2011 Nov 1;20(21):4143-54. doi: 10.1093/hmg/ddr338. Epub 2011 Aug 5.
4
Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin.托伐普坦抑制血管加压素刺激的人 ADPKD 细胞的 ERK 依赖性细胞增殖、Cl⁻分泌和体外囊泡生长。
Am J Physiol Renal Physiol. 2011 Nov;301(5):F1005-13. doi: 10.1152/ajprenal.00243.2011. Epub 2011 Aug 3.
5
A genetic interaction network of five genes for human polycystic kidney and liver diseases defines polycystin-1 as the central determinant of cyst formation.一个与人类多囊肾病和肝脏疾病相关的五个基因的遗传相互作用网络将多囊蛋白-1 确定为囊肿形成的核心决定因素。
Nat Genet. 2011 Jun 19;43(7):639-47. doi: 10.1038/ng.860.
6
Polycystin-1 regulates STAT activity by a dual mechanism.多囊蛋白-1通过双重机制调节 STAT 活性。
Proc Natl Acad Sci U S A. 2011 May 10;108(19):7985-90. doi: 10.1073/pnas.1103816108. Epub 2011 Apr 25.
7
Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.姜黄素通过同时干扰多种信号通路抑制囊肿形成：来自 Pkd1 缺失模型的体内证据。
Am J Physiol Renal Physiol. 2011 May;300(5):F1193-202. doi: 10.1152/ajprenal.00419.2010. Epub 2011 Feb 23.
8
Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis.激活 AMP 激活的蛋白激酶（AMPK）可减缓肾囊肿的发生。
Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2462-7. doi: 10.1073/pnas.1011498108. Epub 2011 Jan 24.
9
PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.过氧化物酶体增殖物激活受体-γ激动剂改善同源大鼠人常染色体隐性多囊肾病模型的肝肾疾病。
Am J Physiol Renal Physiol. 2011 Feb;300(2):F465-74. doi: 10.1152/ajprenal.00460.2010. Epub 2010 Dec 8.
10
Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease.吡格列酮可减轻多囊肾病 PCK 鼠模型的囊状负担。
PPAR Res. 2010;2010:274376. doi: 10.1155/2010/274376. Epub 2010 Nov 1.
Zotero 插件